{"id":"tinzaparin-leo","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Hemorrhage"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tinzaparin exerts its anticoagulant effect by binding to antithrombin III, which accelerates the inhibition of factor Xa and thrombin. This leads to a decrease in the formation of blood clots and an increase in the dissolution of existing clots.","oneSentence":"Tinzaparin is a low molecular weight heparin that acts as an anticoagulant by inhibiting factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:52.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Prophylaxis and treatment of atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT03230162","phase":"PHASE3","title":"Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-06-01","conditions":"Fetal Growth Abnormality, Fetal Growth Restriction","enrollment":100},{"nctId":"NCT01930396","phase":"PHASE4","title":"Use of Tinzaparin for Anticoagulation in Hemodialysis","status":"COMPLETED","sponsor":"Christine Ribic","startDate":"2013-09","conditions":"Kidney Failure, Chronic","enrollment":191},{"nctId":"NCT00851864","phase":"PHASE4","title":"Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2007-10","conditions":"Venous Thromboembolism","enrollment":13},{"nctId":"NCT00628576","phase":"PHASE3","title":"Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"1993-10","conditions":"Deep Venous Thrombosis","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Innohep (Leo)"],"phase":"phase_3","status":"active","brandName":"Tinzaparin (Leo)","genericName":"Tinzaparin (Leo)","companyName":"Aalborg University Hospital","companyId":"aalborg-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tinzaparin is a low molecular weight heparin that acts as an anticoagulant by inhibiting factor Xa and thrombin. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Prophylaxis and treatment of atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}